Tobias Arkenau

13PUBLICATIONS
117CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 16, 2025
Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials.

Rafael Grochot, Kroopa Joshi, Antonella Cammarota

|Mar 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

Markus Moehler, Do-Youn Oh, Ken Kato

|Sep 04, 2024
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.

Babar Bashir, Judy S Wang, Gerald Falchook

|Apr 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.

Duncan A Wheatley, Rossana Berardi, Miguel A Climent Duran

|Jun 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.

Mark Roschewski, Manish R Patel, Patrick M Reagan

|Jun 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.

Nataliya Mar, Yousef Zakharia, Alejandro Falcon

Pageof 3

Frequent Collaborators

4 joint publications

Elisa Fontana

2 joint publications

Ken Kato

2 joint publications

Alastair P Greystoke

2 joint publications

Vivek Subbiah